Low Dose Induction for Pediatric Acute Myeloid Leukemia Patients

the standard induction treatment for pediatric acute myeloid leukemia has high early morbidity and mortality that jeopardize the outcome especially in developing countries. SIOP recommended lower dose induction synergistic G- CSF to minimize these unwanted toxicities. the study aimed at minimizing the toxicities during induction without jeopardizing the survival.

Trial Details

NCT ID
NCT07867600
Phase
NA
Sponsor
Azza Shibl Sayed
Status
RECRUITING
Cancer Type
Acute Myeloid (AML) Leukemia
Interventions
  • Low dose Ara C/ anthracycline combined with GCSF
Locations (sample)
  • Asyut, Asyut Governorate, Egypt|27.18096,31.18368
  • Asyut, Asyut Governorate, Egypt|27.18096,31.18368

Key Eligibility Criteria

  • Denovo pediatric AML patients.
  • equal or \<18 years old

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Acute Myeloid (AML) Leukemia Trials on Trialify →